Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ORX750 in Subjects With Narcolepsy and Idiopathic Hypersomnia (CRYSTAL-1)

NCT06752668 is registered in ClinicalTrials.gov with Centessa Pharmaceuticals (UK) Limited as lead sponsor.

NCT NCT06752668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06752668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ORX750 in Subjects With Narcolepsy and Idiopathic Hypersomnia (CRYSTAL-1)
Lead sponsor
Centessa Pharmaceuticals (UK) Limited
Phase
Phase 2
Overall status
Recruiting
Start date
December 23, 2024
Completion date
December 31, 2026
Enrollment
248 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic hypersomnia, narcolepsy type 1, narcolepsy type 2